Carl Zeiss Meditec: A High-Grade Ophthalmology Franchise Forced to Relearn Its Operating Model in China

That hybrid design solved a real industry need. Ophthalmology and microsurgery reward precision optics, trusted brands, long surgeon training curves and clinical workflow integration. A company that could combine ZEISS optics, diagnostics, lasers and surgical systems underneath one medical banner had a natural right to exist. In the early period, the business model was more heavily anchored in equipment and technology platforms. Over time, management broadened it into a fuller treatment-path model around recurring consumables, service and integrated workflows. The recurring-revenue share rising from about 9% in 2002/03 to roughly 50% in 2024/25 is the cleanest single proof of that shift.

Ownership also shaped the path. Carl Zeiss AG holds about 59% of the shares, with the rest largely in free float and a small treasury-share position. The controlling shareholder sits under the Carl Zeiss Foundation, and investor materials stress that related-party transactions are registered, audited and covered by dependency-report and German related-party rules. That does not eliminate governance discount risk, but it means minority holders are not entering a controller structure without formal protections. In practice, the arrangement gives Carl Zeiss Meditec privileged access to group distribution, shared services and brand strength, while also leaving minority holders dependent on how fairly the controller allocates costs, opportunities and strategic priorities across the group.

The stages that matter

The first stage ran from founding through the early-2000s combination. The company’s growth driver then was category formation: building a quoted medical-technology company around ophthalmic devices and laser systems. The decisive move was creating a platform broad enough to matter in capital markets, not launching any single product. The market originally understood the story as a listed optical-medical growth company with ZEISS pedigree and specialist device exposure. The lasting impact of that stage is still visible in the company’s legal structure, listing history and brand credibility.

The second stage was the long scale-up through the 2010s into the pandemic and immediate recovery. Here the growth engine was broader adoption of ophthalmic diagnostics, cataract and refractive systems, and recurring consumables attached to a growing installed base. Management’s most consequential choice was to widen the “workflow” claim rather than stay a narrow device supplier. The financial signature of that phase was rising revenue, high margins and a steadily more recurring sales mix; the capital-market signature was multiple expansion all the way into the 2020/21 and 2021/22 highs, when the stock traded as a premium structural grower. The share page’s year highs of €199.05 and €191.05 in those two fiscal years capture how fully the market bought that narrative.

The third stage was the post-peak normalization from 2022/23 through 2024/25. Revenue still grew in 2022/23 to €2,089m, but EBIT margin fell to 16.7% from 20.9% as the mix became less favorable and the unusually large recurring-revenue contribution seen in the prior year unwound. Then FY2023/24 brought a more obvious break: revenue slipped to €2,066.1m, currency- and acquisition-adjusted revenue fell 4.8%, and EBIT margin dropped to 9.4%. A strategic positive also arrived in this period: DORC. Carl Zeiss Meditec acquired DORC effective 3 April 2024 for a purchase price of €1,023.7m, partly financed by a €400m shareholder loan from the ZEISS group, broadening the ophthalmology portfolio in retinal surgery and vitrectomy. But a market that was already downgrading the company’s growth quality treated the deal less as a reacceleration and more as a balance-sheet burden added into a weakening cycle.

The fourth stage is the current one: margin trough, China-policy overhang and restructuring. The Q1 FY2025/26 guide suspension was the turning point that forced management to stop talking like a temporarily bruised premium grower and start talking like a company that needed cost, footprint and portfolio surgery. By H1, management had cut full-year revenue expectations to €2.15bn–€2.20bn, guided to an adjusted EBITA margin of 8%–10%, and laid out the ProfitUp plan targeting more than €200m of annual additional earnings contribution by FY2028/29, with up to 1,000 roles potentially affected and cumulative one-off expenses and CapEx of up to €150m. The lasting importance of this stage will be decided by one question: whether ProfitUp restores an old earnings structure, or merely cushions a new, lower one.

The financial vertical review

A compact way to see the business arc is to put revenue, cash generation and the share-price regime side by side.

Source note: annual press releases and annual reports for FY2020/21 to FY2024/25, financial-publications page key figures, H1 FY2025/26 report, and current Xetra quote.

The revenue line tells one story and the margin line tells another. Revenue climbed hard from the pandemic trough through 2022/23, softened in 2023/24, recovered in reported terms in 2024/25 partly because DORC added revenue, and then fell again in H1 FY2025/26. Margins, by contrast, never really recovered after the 2021/22 peak. That is why the stock keeps de-rating. Markets will forgive a bad quarter in equipment-heavy medtech; they do not easily forgive a multi-year march from a 20%+ operating-margin story to a single-digit adjusted EBITA story, especially when part of the historical premium rested on the belief that recurring revenue had made the company sturdier than ordinary capital-goods names.

Cash conversion is better than the earnings collapse alone would suggest, though not pristine. The company’s financial-publications data show operating cash flow of €250.9m in FY2022/23, €247.3m in FY2023/24 and €209.9m in FY2024/25. H1 FY2025/26 operating cash flow rebounded sharply to €98.9m from €8.5m a year earlier, mainly because receivables fell and tax refunds helped. That is useful, but it should not be over-romanticized. Some of the H1 cash improvement was working-capital timing, not a clean sign that earnings quality suddenly improved. Over the last full cycle, Carl Zeiss Meditec has been a cash generator, not a cash burner, but the post-DORC period also shows how acquisitive expansion and inventory-heavy transitions can blur the textbook medtech cash profile.

Balance-sheet soundness is still a strength, but less so than it was before DORC. At 31 March 2026, equity was 63.1% of total assets, goodwill stood at €975.6m, and net financial debt was €274.4m. The FY2024/25 annual report noted that €969.7m of goodwill already represented 29% of total assets and 46% of equity, most of it in ophthalmology. Inventories were €497.2m net at 30 September 2025 and then €538.6m at 31 March 2026, taking inventories to 24.8% of rolling 12-month revenue, up from 22.3% at year-end. Those are not distress numbers, but they are exactly the kind of figures that matter in a reversal case: if the turnaround works, the balance sheet is adequate; if China stays difficult and product rationalization drags, goodwill and inventory become less comfortable than they look today.

Price and valuation history

The stock’s journey can be divided into three valuation regimes. The first was the expansion regime into 2021/22, when high growth, high margins and a premium medtech multiple reinforced one another. The second was the normalization regime from 2022/23 through early 2024, when the market cut the multiple before it fully accepted how much lower margins might go. The third is the credibility regime that began in earnest with the 2024 profit warning and hardened in 2026. In June 2024 the company warned that EBIT for FY2023/24 would be materially below prior expectations because of weaker North American device demand and a slow start to peak refractive season in China. Then in January 2026 it suspended FY2025/26 guidance, and by May it reset the year lower. A stock that once priced future quality now prices uncertainty around the path back to quality.

At today’s price, the market is no longer paying for Carl Zeiss Meditec as a premium medtech compounder. On trailing FY2024/25 earnings per share of €1.61 and a current price of €27.96, the stock trades at roughly 17 times trailing EPS. On FY2024/25 revenue of €2.2276bn, the equity trades at only about 1.1 times trailing sales. Add March 2026 net debt of €274.4m and enterprise value is roughly €2.78bn, or around 1.3 times FY2025 sales and around 14 times the midpoint of FY2026 adjusted EBITA guidance. By the standards of its own history, that is a radically compressed valuation. By the standards of a company whose margin ceiling is being re-litigated, it is only moderately cheap.

Business model, moat and industry

How the revenue machine works

Carl Zeiss Meditec runs two businesses that share optical DNA but behave differently in a downturn. Ophthalmology sells diagnostics, cataract and refractive equipment, intraocular lenses and other surgical consumables. Microsurgery sells surgical visualization systems and microscopes used across neurosurgery and other specialties. Ophthalmology is the larger and economically more important segment. In H1 FY2025/26 it generated €753.8m of revenue against €237.2m for microsurgery. The same half also showed the stress concentration clearly: ophthalmology fell 6.7% reported, 4.2% currency-adjusted, while microsurgery was down 2.1% reported but up 1.8% currency-adjusted. In other words, the strain is concentrated rather than house-wide: it sits mainly in the ophthalmology profit engine, especially the China-sensitive parts of the IOL and refractive mix.

The company’s own presentation places mainland China as its largest market, at about 25% of FY2024/25 revenue, with the U.S. second. That concentration helps explain both the former growth premium and the current pain. China amplified the upside when premium refractive packs and IOLs were growing. It now amplifies the downside because VBP rules, local competition and localization expectations hit exactly where Carl Zeiss Meditec historically enjoyed premium economics. The Americas issue is different. There the problem is not mainly policy; it is investment hesitation around devices. Together those two regions expose the split inside the business model: recurring surgical consumables and installed-base monetization make the business sturdier than pure capital equipment, but not sturdy enough to fully offset a simultaneous miss in China mix and U.S. equipment volume.

The cost structure creates operating leverage in both directions. Gross profit falls quickly when the mix shifts away from premium consumables, implants and higher-value systems; operating expenses do not move quickly enough to compensate. That is exactly what management described in Q1 and H1: currency effects, unfavorable product mix and stable expenses produced negative operating leverage. This is why ProfitUp matters. The point of the restructuring is to lower the breakeven of a business whose prior cost base was built for a different regional and mix environment, not simply to trim fat.

What the moat is and what is only marketing

The first real moat is brand plus clinical trust, especially where ZEISS sits close to the surgeon’s line of sight. In ophthalmology and microsurgery, optical quality and surgical visualization are not abstract features; they shape clinical confidence, training habits and workflow standardization. Investor materials explicitly claim market-leading positions and note that more than 15 million cataract surgeries are performed yearly with ZEISS surgical systems and more than 10 million neurosurgical procedures use ZEISS surgical microscopes. Those kinds of installed-base statements should not be read as a proof of pricing power by themselves, but they are a good measure of how embedded the company is in daily clinical practice.

The second moat is the installed base plus recurring revenue. The climb from 9% recurring revenue in 2002/03 to roughly 50% in 2024/25 matters more than almost any product brochure. It means the company has spent two decades turning one-off equipment placements into a continuing ecosystem of consumables, implants, software and service. That is the best defense Carl Zeiss Meditec has against pure price comparison. In a hospital or clinic, a supplier that touches diagnosis, surgery and post-sale support enjoys a better chance of holding share than a competitor that sells only an instrument.

The third moat is technology depth, sustained by heavy R&D. Investor materials show R&D expense running in the mid-teens as a percentage of revenue in recent years and present a longer-term target above 16%. That level of sustained spending is consistent with a company trying to preserve technology leadership in categories where product cycles are long and surgeon acceptance matters. It also provides a partial explanation for why management chose reprioritization rather than slash-and-burn in the current program: cut too deeply and the company saves this year’s margin at the cost of the next product cycle.

What is weakening is the China leg of the moat. Management said in February that the company was in a period of vulnerability because it had not localized manufacturing fast enough. That is unusually candid, and it means the old premium-import advantage is no longer enough on its own. In China, the moat now has to include local manufacturing presence, regulatory agility and a cost structure that can survive tender pricing. Until that rebuild is visible, it would be wrong to treat the company’s historical moat as unimpaired.

Governance, management and industry cycle

Governance is better than one might expect from a controlled company, but not frictionless. Carl Zeiss AG remains the controlling shareholder at roughly 59%, related-party protections exist, and the supervisory-board structure includes independent shareholder representatives alongside employee representatives. PwC audits the financial statements, and the supervisory board separately reviews the dependency report that follows from the control relationship. Those are important safeguards. Still, there is an unavoidable governance discount whenever a listed minority sits under a dominant industrial parent that also provides treasury, services and strategic direction.

Management credibility is mixed rather than broken. CFO Justus Felix Wehmer has been in place since 2018. Andreas Pecher has served as chairman of the management board on an interim basis since 1 January 2026 after Maximilian Foerst’s short tenure ended on 31 December 2025. The company deserves credit for acknowledging the severity of the current downturn rather than defending the old guidance too long. It also deserves scrutiny because the China vulnerability reveals a lag in localization and strategic adaptation that should arguably have been addressed earlier. The right judgment is that management still has a credible repair path, but no longer enjoys the benefit of the doubt it once had.

Industry-wise, Carl Zeiss Meditec sits in a structurally attractive field with cyclical overlays. Alcon estimates the ophthalmic surgical market at about $14bn and expects 4%–6% annual growth from 2025 to 2030, driven by aging-related cataract demand, retinal procedures, glaucoma interventions and refractive technology upgrades. That makes Carl Zeiss Meditec a demographic-growth company at the top layer. But the current downturn shows the second layer: it also carries equipment-capex exposure, product-cycle exposure, FX exposure and, in China, policy-cycle exposure. This is why the stock reads as neither a pure defensive medtech name nor a pure cyclical, but as both at once. The industry’s underlying demand trend is still favorable; the revenue-to-margin translation can still get ugly for several quarters at a time.

Horizontal competitor analysis

The cleanest direct peer is Alcon. It is the global scale leader in ophthalmic surgery, says it holds the number-one position in that market, and in 2025 generated $5.751bn in surgical revenue, with $1.782bn from implantables, $3.028bn from consumables and $941m from equipment and other surgical products. That profile matters because it shows what Carl Zeiss Meditec is not: it is not the industry’s one-stop scale owner. Alcon’s size lets it spread R&D, manufacturing and commercial infrastructure across a much broader revenue base, and its “one-stop shop” positioning is exactly the kind of breadth that procurement-conscious customers find attractive. Carl Zeiss Meditec fights back with premium workflow positions, optics heritage and strength in microsurgery, but on pure ophthalmic scale it is the challenger, not the incumbent.

Johnson & Johnson Vision is not a good reporting peer because its vision business is buried inside a huge group, but it is a very real product rival where the economics matter most. The 2024 launch of TECNIS Odyssey and the 2026 FDA approval and rollout of TECNIS PureSee show that J&J is pushing hard in premium presbyopia-correcting and EDOF IOL categories. That matters because Carl Zeiss Meditec’s China problem is occurring exactly in a lens category where premium technology and reimbursement rules already make pricing and positioning sensitive. A company that is trying to restore premium IOL momentum does not face only Chinese local players; it also faces multinational rivals with deep product pipelines and large commercial footprints.

Bausch + Lomb is the more useful “middle” peer. It is smaller than Alcon but still large enough to matter, and its FY2025 numbers show a business with $894m of surgical revenue and $5.101bn of total revenue. It is also a reminder that not every ophthalmology peer deserves a premium multiple. Bausch + Lomb still made a net loss in FY2025 despite 6% total revenue growth, and the market values it at roughly 1.08 times sales. That matters for Carl Zeiss Meditec because it frames the downside of sector multiple comparisons: once investors decide ophthalmology is not enough and they want clean earnings quality too, revenue scale alone does not protect the valuation.

In microsurgery, Leica Microsystems under Danaher is the most important strategic reference. Leica explicitly describes itself as a Danaher company and a market leader in surgical microscopes. Yet Danaher is not a clean financial peer either, because Leica sits inside a much larger life-sciences and diagnostics portfolio. That is why Carl Zeiss Meditec can plausibly claim number-one position in microsurgery and still not get paid a high multiple for it. The capital market values Carl Zeiss Meditec mainly through the problems of ophthalmology, while much of the microsurgery competition is buried in conglomerates whose investors are not directly underwriting microscope economics.

Topcon remains relevant as an operating benchmark in ophthalmic diagnostics, even though it agreed to go private in 2025 and is therefore no longer a good listed valuation peer. Its eye-care materials described accelerating sales ex-China in FY2024 and it has cited a number-one OCT position globally in earlier healthcare materials. For Carl Zeiss Meditec, that is a reminder that diagnostic competition is not standing still either. The company’s strength comes from combining diagnosis with therapy rather than dominating every standalone diagnostic category.

A compact numerical picture of the listed peer set makes the gap clearer.

Source note: Carl Zeiss Meditec annual report and current quote; Alcon 2025 annual report and current market-cap data; Bausch + Lomb FY2025 materials and current quote data. Currency translation is not required for P/S and P/E comparisons because those multiples are currency-neutral.

The business reason behind those multiples is straightforward. Alcon gets a premium because it has scale, breadth and stronger proof that its surgical platform can hold margin through the cycle. Bausch + Lomb gets no premium because it still has earnings-quality and leverage questions despite respectable growth. Carl Zeiss Meditec trades much closer to Bausch + Lomb than to Alcon because the market is withholding judgment on whether the company’s old premium economics still apply after China VBP pressure and margin collapse. That discount is justified today. The open question is whether it persists once the China relisting and ProfitUp evidence becomes concrete.

Ecologically, Carl Zeiss Meditec is best described as a premium challenger in ophthalmology and the leader in a narrower microsurgery niche. It takes profit from premium cataract, refractive and visualization workflows rather than from being the industry’s lowest-cost mass supplier. That niche becomes stronger when surgeons and clinics pay for outcomes, workflow efficiency and trust. It becomes weaker when procurement and policy force more decisions onto price, local content and tender mechanics. That is why China matters so much. The current pressure is hitting exactly the part of the market where the firm’s niche is least protected by its traditional strengths.

Current fundamentals, valuation and risk

What is actually happening now

The last four reported quarters show a clear descent. Q1 FY2025/26 revenue fell 4.8% to €467.0m and EBITA fell 77% to €8.1m, for a 1.7% margin. Management blamed currency headwinds, unfavorable product mix, refractive timing around the Chinese New Year, lost bifocal IOL sales in China and weaker neurosurgical microscope mix. In H1, revenue was down 5.7% to €991.0m and adjusted EBITA dropped to €60.5m from €112.6m, taking the adjusted EBITA margin down to 6.1% from 10.7%. Ophthalmology fell harder than microsurgery, and the Americas remained weak. The core fact is that this is a multi-factor earnings squeeze, not one quarter of bad luck, and management now treats it as requiring structural action.

China is the center of gravity. In February management said the bifocal IOL had been withdrawn from the existing VBP tender, meaning it could no longer be sold to public hospitals under that framework, and it warned of around €8m of earnings risk related to product recall and scrapping. Management also admitted the company had not localized manufacturing fast enough. By May, secondary earnings-call coverage reported that a successor bifocal IOL had now obtained registration approval and that the next VBP tender was expected to start around June or July 2026. The official H1 filing does not lock down the tender timing, so the safer conclusion is this: the company now appears to have a product path back into the tender process, but the size, price and profitability of that return are still unknown.

The market is therefore trading two separate things at once. The first is the obvious near-term downgrade: lower FY2026 revenue, lower FY2026 margins, and special effects including impairment, legal expense and recall-related costs. The second is whether ProfitUp can create a credible medium-term bridge back to >15% adjusted EBITA margin by FY2028/29. Management’s own presentation frames the program as more than €200m of annual earnings contribution by then, roughly €40m of which will be absorbed by rising infrastructure costs, leaving more than €160m of net EBITA support. That is enough to matter, but not enough to settle the debate. Investors still need proof that the savings do not simply offset structurally weaker China economics.

Bull and bear divergence

The bull case rests first on franchise quality. Even in a bad half, microsurgery grew 1.8% currency-adjusted and the company still claims leadership positions in microsurgery and the number-two spot in ophthalmology. Second, recurring revenue near 50% and a long history of heavy R&D suggest this is not a low-grade rebound stock. Third, China now looks like a blocked channel rather than a dead category because the successor bifocal IOL has registration approval. Fourth, the stock’s valuation is far below the level once attached to the business and now assumes a permanently diminished earnings profile. If the company can get anywhere close to its medium-term >15% adjusted EBITA target, the share price does not look demanding on normalized earnings.

The bear case rests first on China becoming structural rather than cyclical. Management’s own “vulnerability” language suggests the issue is an operating model that lagged policy reality, not just a tender timing mismatch. Second, goodwill is now large enough that a prolonged earnings reset would make balance-sheet quality look less comfortable. Third, the U.S. and broader Americas investment slowdown means the recovery cannot rely on China alone. Fourth, the restructuring target is large relative to present earnings, which means the execution burden is also large; when a company promises >€200m of earnings contribution off a deeply reduced base, investors should assume a meaningful miss risk. Finally, the company’s margin corridor has already moved once from old high-teens/20%-plus hopes toward a nearer-term >15% medium-term aspiration. That is still good, but it is no longer the same business the market once capitalized.

Valuation analysis

The first discipline here is to look through headline earnings toward owner earnings. Using FY2023/24 and FY2024/25 official data, operating cash flow was €247.3m and €209.9m respectively, against consolidated profit of €180.2m and €142.3m. That means cash conversion over those two years averaged comfortably above net income, even before considering that some accounting drag came from acquisition-related amortization. CapEx has been noisy because of DORC integration and broader footprint investment. A reasonable working assumption for maintenance CapEx is about €35m–€40m a year, with the excess above that level reflecting growth, integration and strategic systems rather than simple upkeep. On that basis, FY2024/25 owner earnings were roughly €170m–€175m, implying a current owner-earnings yield around 6.8%–7.0% at the present equity value. That is better than the headline “problem stock” mood suggests, but it is still based on a year before the full trough became visible in reported margins.

Historically, the stock is cheap relative to its own old premium. The decline from a fiscal-year high of €199.05 in 2020/21 to €27.96 today is an 80%+ compression in price while revenue over that period actually grew. That tells you the de-rating came from earnings and multiple compression, not from revenue collapse alone. It would be wrong, though, to conclude that the stock is automatically cheap just because it used to be expensive. The relevant question is what earnings ceiling the market should now pay for. If the steady-state margin is no longer near the old 18%–20% ambition, the old valuation center is irrelevant.

Peer valuation is useful mainly for framing the range. Alcon’s far richer sales multiple reflects greater scale and a less contested earnings profile. Bausch + Lomb’s valuation shows what happens when ophthalmology exposure is not enough to offset messy profit delivery. Carl Zeiss Meditec sits in the middle qualitatively, but today it trades much closer to the lower end analytically. That discount will narrow only if the company proves that China is a delay-and-localize problem, not a permanent downgrade in premium lens economics.

The scenario framework below uses owner earnings rather than accounting earnings as the primary anchor. This is valuation-scenario analysis within a research framework, not investment advice.

Source note: scenario ranges are built from FY2025/26 guidance, medium-term margin targets, historical cash flow and current equity value.

The expectation gap is concentrated in three variables: first, whether the new bifocal lens actually gets back into the next China tender at economics that matter; second, whether adjusted EBITA can exit FY2026 clearly above the worst H1 levels; and third, whether localization and footprint actions improve competitiveness without visibly weakening innovation. The next earnings prints matter less for their absolute EPS and more for what they say about those three lines. If investors see China relisting, margin stabilization and better Americas orders at the same time, the stock can rerate before full earnings recovery arrives. If one or more of those lines keep stalling, the stock can stay optically cheap for a long time.

On margin of safety, the verdict is not obvious. Current price is below the base-case value but still above the ideal buy zone implied by a 20% discount to the conservative value. The most fragile assumption in the whole framework is China economics, not formal relisting alone. Even if relisting happens, the company could still return at lower tender prices and lower profitability than investors once assumed. If base-case owner earnings were cut to 70% of the target range, the base valuation would slide toward the high-20s to low-30s, which is too close to the current share price to call the present entry point obviously safe. A useful independent check comes from rates: Germany’s 10-year Bund yield was around 2.85%–2.86% on 25–26 June 2026, while Carl Zeiss Meditec’s current equity value implies a materially higher through-cycle owner-earnings yield. That keeps the stock from being absurdly priced, without making its margin of safety comfortable. The right verdict is not obvious.

Risk, catalysts and tracking dashboard

The biggest business risk is that China turns from temporary blockage into permanent margin erosion. Probability is medium; impact is high. The observable indicator is whether the successor bifocal IOL is relisted on economic terms that restore meaningful contribution, not merely whether the next VBP tender starts. The transmission path is direct: weaker tender economics hit ophthalmology revenue mix, lower mix hits gross margin, lower margin slows ProfitUp credibility, and valuation remains stuck near a low-end medtech multiple.

The second risk is restructuring under-delivery. Probability is medium; impact is high. ProfitUp targets more than €200m of annual earnings contribution by FY2028/29 and may affect up to 1,000 positions, with up to €150m of cumulative one-off costs and CapEx. Programs of that size rarely land exactly on plan. If savings come later or lower than promised, the market will stop underwriting the margin-restoration bridge and start capitalizing the business on a lower steady-state profitability base.

The third risk is that the Americas equipment slowdown persists. Probability is medium; impact is medium to high. The company has already described a weak investment climate in the region, especially the U.S. If capex hesitancy lasts beyond FY2026, Carl Zeiss Meditec loses an important offset just when China is supposed to normalize. That combination would make the trough deeper and longer than current recovery models assume.

The fourth risk is balance-sheet quality erosion through goodwill rather than leverage. Probability is low to medium; impact is medium. The company is not overlevered in a classic sense, but goodwill remains large after DORC. If medium-term cash flows disappoint, the issue is a perception shift rather than immediate solvency: investors can quickly move from seeing DORC as strategic breadth to seeing it as expensive goodwill tied to a weaker market.

The positive catalysts are equally clear. A confirmed relisting path into China VBP, an H2 margin exit better than the full-year guidance implies, and evidence that localization progresses without destabilizing product quality would all matter. So would cleaner Americas order flow and sustained currency-adjusted growth in microsurgery, because both would show that the company is not relying on one single China event to repair the story.

A compact dashboard helps separate noise from signal.

Source note: thresholds are built from recent management disclosures and balance-sheet ratios, especially H1 FY2025/26.

What matters in this dashboard is sequence, not any single reading. If relisting improves but inventories keep swelling and margins do not lift, the recovery is cosmetic. If margin improves but recurring revenue share falls, the company may simply be getting a temporary mix benefit. The dashboard should therefore be read as a chain: China access, segment growth, margin, working capital, then market confidence.

Cross-synthesis summary

Carl Zeiss Meditec’s long journey proves one real capability beyond dispute: it knows how to turn optical and surgical technology into clinically embedded platforms rather than isolated devices. That is why the company got as far as it did. The old success was not luck. It came from technology depth, brand trust, surgeon relationships, a rising recurring-revenue share and, very importantly, the ability to sit inside the broader ZEISS ecosystem while still behaving like a listed medtech specialist. Those factors are still present. What changed is that one of the most profitable regional expressions of that capability, premium ophthalmology in China, is now being filtered through a harsher policy and localization lens. The company therefore enters this cycle as a high-grade franchise being forced to relearn part of its operating model, no longer the clean quality-growth story it once was.

That makes the central investment judgment delicate. A low-quality turnaround can look cheap for a while and still deserve to fail. Carl Zeiss Meditec is not that. But the opposite mistake is also easy: to assume that because the business is good, the market has overshot and the stock must therefore be a buy. The evidence is not strong enough for that leap. The company’s underlying strengths are still visible in recurring revenue, microsurgery resilience, R&D commitment and category position. The reasons for caution are equally visible in management’s own language about China vulnerability, in the scale of the restructuring required, in the still-weak Americas investment climate, and in the fact that the official H1 outlook is a lowered one rather than a reaffirmation of a rebound already under way.

What the market is most likely misjudging right now is not the existence of the problem, but the shape of the resolution. The market seems close to assuming that one of two things must be true: either the old premium economics come back in recognizable form, or the company has permanently lost them. Reality is likely to sit between those poles. China may come back, but on leaner economics and a more localized footprint. Carl Zeiss Meditec may restore margins, just not back to the old premium-growth narrative quickly enough for the stock to be revalued as if 2021 never happened. That is why a patient investor should focus less on the headline 2028/29 target and more on the intermediate bridge: relisting, localization, mix, order trends and margin exit. The next year decides whether the bridge is credible. The next three to five years decide what the new margin ceiling really is.

For the next year, the critical variables are China tender progress, H2 FY2026 margin stabilization and whether Americas orders stop deteriorating. For the next three years, what matters is whether ProfitUp truly lowers the cost base and whether the company can recover enough ophthalmology mix to push adjusted EBITA back toward the mid-teens. For five years, the question becomes larger: can Carl Zeiss Meditec remain a premium, innovation-led ophthalmology and microsurgery company in a world where China rewards local cost structures more aggressively than before? If the answer is yes, today’s valuation will eventually look too low. If the answer is only partly yes, the stock may still work from here, but less spectacularly than trough bulls imagine.

Bull reasons

• The company still holds meaningful market positions, including management’s claim of number two in ophthalmology and number one in microsurgery, and microsurgery remained positive on a currency-adjusted basis in H1 FY2025/26.
• Recurring revenue has risen from about 9% two decades ago to roughly 50% today, which gives the franchise a real installed-base tail that many device businesses lack.
• The successor bifocal IOL has obtained registration approval in China, so the company now appears to have a technical path back into the next VBP cycle rather than a permanently closed door.
• The stock now trades on a compressed sales and earnings base rather than on old premium-growth assumptions, so successful execution on even a partial margin recovery could produce material upside.

Bear reasons

• Management itself described a period of “vulnerability” in China because manufacturing localization had not moved fast enough, which suggests a structural operating-model gap rather than a mere one-quarter stumble.
• H1 FY2025/26 adjusted EBITA margin fell to 6.1% from 10.7%, and Q1 margin fell to 1.7%, showing how severely the business punishes weak mix and low volume.
• Goodwill remains high after DORC, so a prolonged earnings reset would not create an immediate leverage crisis but could still damage balance-sheet quality and investor confidence.
• ProfitUp promises more than €200m of annual earnings contribution by FY2028/29, a very large bridge relative to current profitability, so execution risk is intrinsic rather than marginal.

Pre-mortem

A plausible three-year down-50% script is this: the next China VBP round does begin, but Carl Zeiss Meditec returns only at pricing far below the old premium structure, while local competitors keep taking share in public hospitals. Ophthalmology revenue recovers in volume but not in mix, adjusted EBITA margin stalls near 9%–10% instead of moving toward 15%, and investors stop believing the medium-term target. In that case the stock could be valued more like a low-growth device company at around 0.8x–0.9x sales, which would imply a share price in the mid-teens. That would be a 40%–50% loss path from today.

A second script is more Western than Chinese: U.S. and Americas device demand stay soft through FY2027, ProfitUp savings arrive slower than advertised, and the company cuts R&D or commercial intensity enough to weaken its product pipeline and surgeon momentum. The market would then conclude that management bought time but not a franchise reset. A stock already deprived of its premium could compress further if the recovery loses its “quality” element as well as its “growth” element.

Final research conclusion

Carl Zeiss Meditec is still a real medical-technology franchise. The stock is not being propped up by fashion, and the core business is not a shell. The long record of installed-base growth, recurring revenue expansion and category relevance in ophthalmology and microsurgery remains visible. But the company is no longer entitled to the valuation language it enjoyed at the peak. China has become the proving ground for whether the old moat can survive a world of localization pressure and tender economics, and management’s own restructuring plan shows that the company accepts the need to rework its cost base and footprint rather than wait for demand alone to rescue margins.

At the current price, I do not think the shares are obviously expensive, and I also do not think they offer enough margin of safety to warrant a straightforward buy call for a balanced investor. The valuation now gives tangible credit to the damage, but it still asks investors to trust a medium-term repair path that has not yet been proven. The right stance is to remain engaged and selective: either demand a better entry price, or demand harder evidence that China relisting, localization and margin recovery are actually happening. What would change my mind faster is a clean combination of three things: visible China progress, an H2 FY2026 margin exit well above the H1 trough, and proof that ProfitUp savings are arriving without a visible degradation in product momentum.

【Company-profile scores】

• Fundamental quality: medium
• Growth: medium
• Moat: medium
• Financial soundness: medium
• Management credibility: medium
• Valuation attractiveness: medium
• Risk level: medium
• Suitable investor type: cyclical

【Investment rating】

• Rating: Watch
• One-line thesis: A high-quality medtech franchise in a real trough, but the China relisting and margin-restoration bridge is still too unproven for a clean entry.
• Three price signals:
  • 【Ideal Buy Price】24–26 EUR Basis: at least a 20% discount to the €30–32 per-share value implied by the conservative owner-earnings scenario.
  • Acceptable hold price: 29–41 EUR
  • Clearly overvalued price: 47–54 EUR
• Current-price classification: outside the three bands
• Whether to wait for a better price: yes. A purchase becomes more attractive either at €24–26, or at a somewhat higher price if China relisting and H2 margin recovery are both visible. The opportunity cost of waiting is that a successful FY2026 H2/FY2027 rerating could happen before full earnings normalize.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative about 2%–5%; base about 7%–10%; optimistic about 14%–20%
• Max-loss risk: roughly 40%–50% if China returns at structurally lower economics and the market values the company as a lower-margin device business rather than a premium medtech franchise
• Reassessment-trigger signals:
  • if the successor bifocal IOL is not relisted into the next relevant China VBP cycle on workable commercial terms
  • if adjusted EBITA margin stays below 8% for two consecutive quarters after the restructuring should be taking effect
  • if inventories remain above 25% of rolling sales without matching revenue recovery
  • if microsurgery turns negative on a currency-adjusted basis for two consecutive quarters
  • if management materially cuts the FY2028/29 margin-restoration framework within the next 12–18 months

【Valuation Range】

• current: 27.96 (close as of 2026-06-25)
• bear (conservative · ideal buy zone): [24, 26]
• base (fair · acceptable hold zone): [29, 41]
• bull (optimistic · above the clearly-overvalued line): [47, 54]

Research uncertainties

The first blind spot is China detail. The official filings confirm the withdrawal from the existing VBP framework and the subsequent recall effects, but the precise economics of the next tender round remain unknown, and some of the color on timing and registration comes from earnings-call summaries rather than the formal filing itself.

The second blind spot is maintenance versus growth CapEx. The company discloses cash investment levels, but any owner-earnings split between maintenance and growth spending still requires judgment. The valuation ranges above therefore depend on a conservative but not directly disclosed maintenance-CapEx assumption.

The third blind spot is peer purity. Alcon is the best listed ophthalmic peer, but Johnson & Johnson Vision and Leica/ Danaher are strategically important competitors whose economics are not cleanly separable in public reporting. That complicates peer-multiple work.

The fourth blind spot is restructuring quality. Management has disclosed the scale of ProfitUp, but investors still do not know which savings will prove durable, which will be offset by reinvestment, and whether execution will affect innovation cadence more than planned.

Sources

Primary materials used in this report were the Carl Zeiss Meditec FY2024/25 annual report, the FY2025/26 six-month report, the FY2025/26 first-quarter statement and transcript, the FY2023/24 annual report, the ZEISS investor presentation materials, the corporate-governance page and share-data page, together with official or primary competitor filings from Alcon, Bausch + Lomb, Danaher/Leica and Johnson & Johnson. Secondary sources were used sparingly where management commentary from the May 2026 earnings call was not reproduced in full in the formal filing, especially on China VBP timing and the successor bifocal IOL registration update.

Other tickers mentioned

• ALC.US — the cleanest listed ophthalmology peer and the global scale leader in ophthalmic surgery
• JNJ.US — product-level rival in premium IOLs and refractive platforms through Johnson & Johnson Vision
• BLCO.US — smaller ophthalmology peer that helps anchor the lower end of the sector’s valuation range
• DHR.US — owner of Leica Microsystems, an important microsurgery and surgical-microscopy competitor

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.